Dr. Grey AI

Zeaxanthin

Zeaxanthin is one of three macular carotenoids (with lutein and meso-zeaxanthin) that accumulate in the macula and protect against blue light and oxidative damage. AREDS2 formula includes 2mg zeaxanthin + 10mg lutein. Together they reduce AMD progression risk. Zeaxanthin is more concentrated in central macula than lutein. Found in orange peppers, corn, egg yolks. Generally used with lutein, not alone.

Quick Answer

What it is

Zeaxanthin is one of three macular carotenoids (with lutein and meso-zeaxanthin) that accumulate in the macula and protect against blue light and oxidative damage. AREDS2 formula includes 2mg zeaxanthin + 10mg lutein.

Key findings

  • Grade B: AMD Progression Risk
  • Grade B: Macular Pigment Optical Density
  • Grade C: Contrast Sensitivity

Safety

  • Together they reduce AMD progression risk.
  • Multiple observational studies including the CAREDS ancillary study of the Women's Health Initiative found higher macular pigment density and dietary intake associated with reduced AMD risk, though zeaxanthin is typically co-administered with lutein.
ℹ️ Quick Facts: Zeaxanthin

Quick Facts: Zeaxanthin

  • Best Evidence:Grade C
  • Conditions Studied:2
  • Research Outcomes:7
  • Grade B Findings:2
  • Key Effect:Cataracts
Outcomes by grade:
A0
B2
C3
D2
2 conditions · 7 outcomes

Detailed Outcomes

|
B
AMD Progression Risk
The large AREDS2 RCT (n≈4,203) demonstrated that lutein/zeaxanthin (10mg/2mg) reduced AMD progression, with greatest benefit when replacing beta-carotene. Multiple observational studies including the CAREDS ancillary study of the Women's Health Initiative found higher macular pigment density and dietary intake associated with reduced AMD risk, though zeaxanthin is typically co-administered with lutein.
moderate↓Improves
B
Macular Pigment Optical Density
Multiple human supplementation trials consistently show that zeaxanthin (typically combined with lutein and/or meso-zeaxanthin) significantly increases macular pigment optical density (MPOD). A 2017 JAMA Ophthalmology RCT and several earlier trials in both AMD patients and healthy adults confirmed dose-dependent MPOD increases over 6-24 months of supplementation.
moderate↑Improves
C
Contrast Sensitivity
Several human trials report modest improvements in contrast sensitivity following macular carotenoid supplementation. An RCT in early AMD patients (PMID:22858124) and the ZVF study in atrophic AMD (PMID:22027699) showed improvements, though effects in healthy eyes were more modest and not all studies reached significance.
small↑Improves
C
Disability Glare Recovery
A controlled trial (PMID:27857944) found macular carotenoid supplementation including zeaxanthin improved disability glare performance and photostress recovery dynamics. The ZVF study also reported glare recovery improvements in atrophic AMD patients supplemented with zeaxanthin, though the evidence base remains limited.
small↑Improves
D
Diabetic Retinopathy Risk
A narrative review (PMID:28232380) discussed a putative protective role of lutein and zeaxanthin in diabetic retinopathy based on antioxidant mechanisms and limited preclinical data. An exploratory study (PMID:27274188) evaluated macular carotenoid supplementation in various retinal diseases including diabetic retinopathy, but robust clinical trial evidence is lacking.
small↓Improves
C
Nuclear Cataract Risk
The CAREDS ancillary study of the Women's Health Initiative (PMID:18332316, n≈1,787) found inverse associations between dietary and serum lutein/zeaxanthin and age-related nuclear cataract prevalence. Evidence is primarily observational and the independent contribution of zeaxanthin versus lutein is unclear.
small↓Improves
D
Cognitive Function
Preliminary evidence suggests a possible role for lutein and zeaxanthin in cognitive function in the elderly (PMID:23053547). A primate study (PMID:22780947) demonstrated that macular lutein and zeaxanthin concentrations are correlated with brain carotenoid levels, providing a plausible biological mechanism, but human intervention data remain very limited.
small↑Improves

Related Supplements

Whole Coffee Fruit Extract

1 shared condition · 3 outcomes

Whole Coffee Fruit Extract (NeuroFactor brand) is marketed for increasing BDNF (brain-derived neurotrophic factor) levels. Made from the coffee cherry (fruit around the bean), NOT coffee beans. Contains polyphenols including chlorogenic acid. Little to no caffeine. One small study showed 143% BDNF increase with 100mg. Limited human evidence beyond BDNF marker. Claims exceed evidence - BDNF increase doesn't automatically translate to cognitive benefits.

Vitamin E

1 shared condition · 274 outcomes

Vitamin E is a fat-soluble antioxidant that protects cells from oxidative damage and is found in several common foods. Supplementing with extra vitamin E does not have broad health benefits, except in people with vitamin E deficiency, and long-term high-dose supplementation may cause harm.

Vitamin C

1 shared condition · 262 outcomes

Vitamin C, or ascorbic acid, is an essential vitamin and a very popular supplement due to its antioxidant properties, safety profile, and low price. Many people supplement with vitamin C because it is believed to reduce symptoms of the common cold.

Vitamin B12

1 shared condition · 18 outcomes

Vitamin B12 is an essential water-soluble vitamin that plays a role in neurological function and is important for DNA synthesis.

Sweet Flag

1 shared condition · 8 outcomes

Sweet flag (Acorus calamus) is a traditional herb used in Ayurveda and TCM for cognitive enhancement. DANGEROUS: Contains β-asarone, a KNOWN CARCINOGEN that causes intestinal tumors and organ damage in long-term studies. BANNED or restricted in many countries including the US (not allowed in food). NOT RECOMMENDED for supplementation due to cancer risk. Despite traditional use, the toxicity profile makes this herb unsuitable for modern use.

Sunifiram

1 shared condition · 4 outcomes

Sunifiram is a RESEARCH CHEMICAL, not an approved drug or supplement. It's a synthetic piracetam derivative with AMPAkine properties. NO GRADED OUTCOMES and NO human clinical trials. Sold in nootropic markets without safety data. NOT FDA approved. Animal studies show cognitive effects at very low doses, but human safety and efficacy are UNKNOWN. CAUTION advised - this is an experimental compound without established safety profiles.

Spikenard

1 shared condition · 8 outcomes

Spikenard (Jatamansi) is an Ayurvedic herb traditionally used for calming, cognitive enhancement, and neuroprotection. Similar traditional uses to Bacopa but with less research. Contains sesquiterpenes and volatile oils. NO GRADED OUTCOMES - human research is very limited. Preclinical studies show neuroprotective potential. Traditionally used for epilepsy, anxiety, and memory. The plant is endangered due to overharvesting; sustainable sourcing is a concern.

Salidrosides

1 shared condition · 11 outcomes

Salidroside is a glucoside compound and one of the main bioactive constituents of Rhodiola rosea. Often standardized in Rhodiola extracts (typically 1-3%). Has neuroprotective and adaptogenic properties. Research shows anti-fatigue, anti-stress, and potential anti-depressant effects. Mechanism involves HPA axis modulation, AMPK activation, and antioxidant effects. Most clinical evidence is for the whole Rhodiola rosea extract rather than isolated salidroside. May be more effective as part of whole plant extract than in isolation.